Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 10;8(5):122–141. doi: 10.5500/wjt.v8.i5.122

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

Treatment of complement factor H autoantibody-mediated atypical hemolytic uremic syndrome. There are no prospective controlled studies in patients with atypical hemolytic uremic syndrome (aHUS) due to anti–factor H protein (FH) antibodies, and thus the proposed management is based on a pediatric consensus[84] (Adapted from: Goodship et al[58]). ^aAbnormal titer depends on the testing laboratory; ^bThe decision to use plasma therapy versus eculizumab will be based on patient age and local resource availability; ^cCyclophosphamide, rituximab, or mycophenolate mofetil; ^dThe decision to continue anticomplement therapy indefinitely is not informed by data; ^eThe interval may be monthly or quarterly and is based on local resources; ^fThis recommendation is based on limited retrospective case reviews[172-174].